Literature DB >> 16176298

Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism.

Birgit A Neudecker1, Robert Stern, Leslie A Mark, Steven Steinberg.   

Abstract

BACKGROUND: Patients with renal failure have been identified recently, some on dialysis, others with renal transplants, who have scleromyxedema-like skin changes. These lesions are characterized grossly by extensive thickening of skin, brawny pigmentation, papules, and subcutaneous nodules. Mucinous deposits are observed histologically that resemble those in scleromyxedema.
METHODS: Biopsies of these lesions were stained with a biotinylated hyaluronan (HA)-binding protein coupled to an avidin-peroxidase reaction.
RESULTS: These lesions are associated with marked deposition of HA in the papillary dermis.
CONCLUSIONS: HA turnover is cleared rapidly in the circulation by both liver and kidney. Evidence suggests that high molecular size HA chains, which are anti-inflammatory, antiangiogenic, and immuno-suppressive are cleared by the liver. By contrast, intermediate-size fragments, which are highly angiogenic, inflammatory, and a stimulus for fibrous deposition, are cleared by the kidney. The accumulation of such fragments in renal failure can account for HA deposition in the dermis and may be a mechanism for the nephrogenic fibrosing dermopathy that can accompany these lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16176298     DOI: 10.1111/j.0303-6987.2005.00415.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  10 in total

1.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

2.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

3.  Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent.

Authors:  Narasimharao Bhagavathula; Marissa DaSilva; Muhammad N Aslam; Michael K Dame; Roscoe L Warner; Yiru Xu; Gary J Fisher; Kent J Johnson; Richard Swartz; James Varani
Journal:  Invest Radiol       Date:  2009-08       Impact factor: 6.016

Review 4.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

5.  Stimulation of fibroblast proliferation by insoluble gadolinium salts.

Authors:  Katherine Bleavins; Patricia Perone; Madhav Naik; Muneeb Rehman; Muhammad N Aslam; Michael K Dame; Sasha Meshinchi; Narasimharao Bhagavathula; James Varani
Journal:  Biol Trace Elem Res       Date:  2011-09-01       Impact factor: 3.738

6.  Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent.

Authors:  Patricia A Perone; Stephanie L Weber; Marissa DaSilva; Tejaswi Paruchuri; Narasimharao Bhagavathula; Muhammad N Aslam; Michael K Dame; Kent J Johnson; Richard D Swartz; James Varani
Journal:  Invest Radiol       Date:  2010-01       Impact factor: 6.016

Review 7.  Hyaluronan as an immune regulator in human diseases.

Authors:  Dianhua Jiang; Jiurong Liang; Paul W Noble
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

8.  Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects.

Authors:  Marissa DaSilva; Monica O'Brien Deming; Suzanne E G Fligiel; Michael K Dame; Kent J Johnson; Richard D Swartz; James Varani
Journal:  Invest Radiol       Date:  2010-11       Impact factor: 6.016

Review 9.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

Review 10.  Gadolinium and nephrogenic systemic fibrosis: time to tighten practice.

Authors:  Iosif A Mendichovszky; Stephen D Marks; Clare M Simcock; Oystein E Olsen
Journal:  Pediatr Radiol       Date:  2007-10-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.